Xalnesiran sodium is under clinical development by Dicerna Pharmaceuticals and currently in Phase II for Hepatitis B. According to GlobalData, Phase II drugs for Hepatitis B have a 36% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how Xalnesiran sodium’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Xalnesiran sodium overview
Xalnesiran sodium is under development for the treatment of chronic hepatitis B. The therapeutic candidate is administered through subcutaneous route. It is developed based on GalXC platform that extends dicer substrate short interfering RNA (DsiRNA-EX) technology conjugated to a targeting agent to enable delivery to the liver.
Dicerna Pharmaceuticals overview
Dicerna Pharmaceuticals (Dicerna) is a biopharmaceutical company that discovers and develops therapeutics for the treatment of rare inherited diseases and cancers. The company’s lead product DCR-PHXC is used for the treatment of primary hyperoxaluria (PH). It offers RNAi technology platform GalXCTM is an advanced next-generation RNAi-based therapies that is designed to silence disease-driving genes in the liver. Dicerna’s GalXC-based therapies are processed by the Dicer enzyme, which is the natural initiation point for RNAi within the human cell. The company also develops therapies to treat diseases linking the liver includes rare, viral infections, chronic liver, and cardiovascular diseases. Dicerna is headquartered in Lexington, Massachusetts, the US.
For a complete picture of Xalnesiran sodium’s drug-specific PTSR and LoA scores, buy the report here.